Join our panel of experts tomorrow for a "How to Optimize Drug Access among Oncology Stakeholders?" webinar taking place Tuesday, May 21st at 1pm ET. Attendees will get to dive into these and more thought-provoking questions: The Situation – How do we structure and strategize to bring successful products to market within the complexity that is oncology access? The Challenge – How much will health system and payer access management change? The Solution – What can manufacturers do to optimize success? Register now: https://lnkd.in/eEGqw56p
Precision Value & Health’s Post
More Relevant Posts
-
Today's newsletter includes some musings on PhRMA's latest "Medicines in Development" report, which quantifies how mind-blowingly broad innovation in oncology is right now. But it also shows the importance of positive incentives in driving the kind of innovation we all want to see. https://lnkd.in/gqdUN7Q4
To view or add a comment, sign in
-
🚨Patient Preferences & Motivators Matter!!🚨 🔬 Imagine the power of truly understanding patient choices beyond your clinical trials and FDA-approved therapies. At Leal Health, we don't just focus on enrolling patients and matching them to standard of care options; we delve deeper into their decision-making process. 📊 We're proud to introduce a new capability that offers a comprehensive view of the patients who chose alternative paths. With Leal Health, you can now see: ✔️What options they selected ✔️What barriers led to those choices ✔️What aspects were more attractive about their alternatives 💡 This insight is invaluable for refining your strategies, improving patient engagement, and ultimately driving better outcomes. By understanding the full picture, you can enhance your offerings and ensure they resonate more effectively with patients. Partner with Leal Health to gain a deeper understanding of patient motivations and make more informed decisions. Together, we can shape the future of oncology care. #Pharmaceuticals #Oncology #ClinicalTrials #PatientInsights #HealthcareInnovation #LealHealth
To view or add a comment, sign in
-
If you wondered why oncology is a big topic at the J.P. Morgan Healthcare conference.😉 On a more serious note, I understand better why the biotech indexes tend to move higher during the conference. often beating all other sectors. So much people, so much news, so much announcements, it is amazing how the conference bring the whole biopharma world together. Now it is time to bring back and reflect on all of that information to better serve our clients. atonra #JPMHC24
To view or add a comment, sign in
-
-
The primary goal of the ZbadajRaka.pl Registry is to shorten the path of a patient in need to targeted treatment. How does it work in practice? Every oncology patient can complete the form, thanks to which they will be under the care of our medical team. 🥼 During the telephone interview, he will be asked key questions that will allow him to determine the current status of the patient and, if necessary, start looking for appropriate treatment. 🩺 If there is a treatment from which the patient may potentially benefit, he or she will be informed about it along with the path to access the drug (NFZ drug program, emergency access to drug therapies, clinical trial). It may be that there is no current treatment available. However, the search does not stop and the patient will be informed when the situation changes. More about the work of the Register can be found at: https://lnkd.in/dE9dSE8b. #CancerTreatment #ZbadajRakaPl #PatientRegistry #OncologyCare #MedicalSupport #HealthcareAccess #ClinicalTrials #TargetedTherapy #PatientCare #CancerResearch
To view or add a comment, sign in
-
-
Unlock the power of data triangulation in #RareDisease and niche oncology. Discover how an emerging #biopharma company leveraged IQVIA's proprietary datasets to understand patient profiles, healthcare provider characteristics, and generate valuable business and scientific insights to guide HCP engagement. Download our case study now. https://bit.ly/3UUjNUp
To view or add a comment, sign in
-
-
The data triangulation approach used for this case study can generate detailed insights to answer to any business questions by triangulating our IQVIA proprietary datasets in Real World Evidence, Drug Sales and Prescription, Biomedical Literature analysis, HCP and KOL information and Primary Intelligence. Send me a PM if you would like to hear more about it. #RareDisease #biopharma #IQVIA
Unlock the power of data triangulation in #RareDisease and niche oncology. Discover how an emerging #biopharma company leveraged IQVIA's proprietary datasets to understand patient profiles, healthcare provider characteristics, and generate valuable business and scientific insights to guide HCP engagement. Download our case study now. https://bit.ly/3UUjNUp
To view or add a comment, sign in
-
-
This week, our team members John Hennessy, Douglas Bock, and Katie Rapp will share key takeaways for our manufacturer clients from the Value-Based Cancer Care conference #AVBCC. In its 13th year, this conference includes 325 faculty members participating in 90+ panel discussions, all focused on oncology. We'll share top takeaways for #pharma and #biotech throughout the conference. The meeting kicked off with conversations on the future of value-based care and the impact of the Inflation Reduction Act (#IRA). Here's what our clients need to know: - Stakeholders define "value" differently; it's essential to understand how your customer defines value so you are speaking the same language. - With VBAs, payers are most interested in four areas: 1. If the product is expensive, does it add significant value compared to the standard of care? 2. Is there significant market competition among innovative therapies? 3. What is the total cost of care? 4. Where does the uncertainty lie around the value of the product? - The high costs of oncology therapies drive payers to prioritize value-based agreements (#VBAs). - Stakeholders want pharma to come to the table with value solutions, but those solutions don't always have to center around refunds. Other solutions may include funding alternative therapies or providing support solutions. - All agree that the perfect storm is brewing for VBAs, and those who aren't prepared are likely to suffer the consequences. - With the right approach, VBAs may evolve into an IRA negotiation tool. - Panelists agree that "negotiation" is a misnomer when it comes to the IRA. Follow along with us this week for updates on the issues impacting #oncology manufacturers across #marketaccess, #pharmaceuticaldistribution, #patientsupport, #payerrelations, and more. Valuate Health Consultancy Archbow Consulting
To view or add a comment, sign in
-
-
In January 2022, the European Commission published a milestone regulation enforcing a joint approach to clinical assessments across the European Union. This joint clinical assessment (JCA) of technologies will begin with oncology therapies in January 2025. Here, we outline the upcoming JCA process and give some thoughts to its benefits and drawbacks. At HEOR, we look forward to using our HTA experience to support our clients in strategically navigating this new landscape and aiding patient access to life-changing medicines. Click the link below to download the full white paper. https://lnkd.in/egcHW3hE #heor #hta #europeancommission #patientaccess #consultancy
To view or add a comment, sign in
-
-
Oncology Domains For Sale. Common terms that drive traffic to your brand's website. Mind share into market share. LiquidCancer.com ; LiquidTumor.com ; LiquidTumors.com ; LiquidTumour.com ; LiquidTumours.com
To view or add a comment, sign in
-
#Cancer_Supportive_Care_Products Market - Upcoming Business Future Growth and Forecast To 2032. >> https://lnkd.in/dBu3v4kW The increase in the rise of #cancer #cases and rising #awareness of supportive care products will drive the #growth of this #market. The increase in the spending capacity and improved #health #care has made it possible for a wider population to use these products which in-turn is adding to the market revenue. Amgen Merck Group Johnson & Johnson Heron Therapeutics, Inc. Novartis TESARO, Inc. F. Hoffmann-La Roche Ltd Helsinn Group #Cancer_Supportive_Care_Products #healthcare #business_opportunities #marketanalysis #marketresearch #opportunities #business #future
To view or add a comment, sign in
-
Madeline Waldron, PharmD, BCOP, Cherry Chen Moldovan, Ph.D., Christy Banach, Erin Lopata, Jeanette Lazusky